Skip to content
value.today

Calysta BioSystems LLC

🇺🇸 Menlo Park, California, USABiotechnologyFounded 2011
Total raised
$50 M
2 rounds on record
Latest round
$45 M
Jun 2019
First round on record
May 2011
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Calysta BioSystems LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$45 MNo. 2$10 to $50 million

Calysta BioSystems LLC: Raise no. 2, Jun 2019

Investors in this round

18 investors had bought by the notice of Oct 11, 2019: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$45 M of $120 M offered; $75 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Shaw, Ph.D. · Executive Officer, Director
  • Craig Barratt, Ph.D. · Director
  • David Hayes · Director
  • Mike Swee Velings · Director
  • Rich Swee Torres · Director
  • Suan Swee Tan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan Shaw, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 11, 2019. Read the notice at the SEC.

equitySEC
May 2011$5 MNo. 1$2 to $10 million

Calysta BioSystems LLC: Raise no. 1, May 2011

Investors in this round

32 investors had bought by the notice of May 26, 2011: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$410,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • David McElroy · Executive Officer, Director
  • Joshua Silverman · Executive Officer
  • Claes Gustafsson · Director
  • Jeremy Minshull · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes up to 5,000,000 of Class A shares for $1.00/share; 6,849,999 of Class B shares for $0/share; and 950,000 of Class C shares for $0/share”
  • On the use of proceeds: “The amount above is an estimate of the aggregate amount to be paid to the named persons over the next year.”

Signed by David McElroy, President, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed May 26, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Calysta BioSystems LLC chose not to state its revenue in its newest notice of a funding round (Oct 2019).

    SEC Form D · Oct 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2019

That is all the official record says: Calysta BioSystems LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Calysta BioSystems LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 32 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Calysta BioSystems LLC
NameRoleNamed in
Alan Shaw, Ph.D.Executive officerOct 2019
David McElroyExecutive officerMay 2011
Joshua SilvermanExecutive officerMay 2011
Alan Shaw, Ph.D.DirectorOct 2019
Craig Barratt, Ph.D.DirectorOct 2019
David HayesDirectorOct 2019
Mike Swee VelingsDirectorOct 2019
Rich Swee TorresDirectorOct 2019
Suan Swee TanDirectorOct 2019
Claes GustafssonDirectorMay 2011
David McElroyDirectorMay 2011
Jeremy MinshullDirectorMay 2011